The SARS-CoV-2 pandemic and the long-term neurological complications that resulted in patients, referred to as long-coronavirus disease , have rekindled interest in the relationship between viral infections and neurodegenerative brain illnesses.
About the study In the present study, researchers demonstrated that ex vivo protein amyloid aggregation was caused by HSV-1 and ultraviolet -inactivated SARS-CoV-2 in the human CSF. Furthermore, the amyloid aggregates produced by the viruses were collected and purified in order to describe the proteins found in the amyloid fractions. This was achieved by washing, centrifuging, and solubilizing the amyloid fraction in 99% formic acid after removing the associated non-amyloid proteins with 4% sodium dodecyl sulfate .
Related StoriesConcerning the proteins present in untreated CSF, the proteomic analysis showed that a significant number of proteins were enriched in the virus-induced amyloid fractions. In comparison to untreated CSF, 279 proteins were found to be enriched in the virus-induced amyloid fractions. The amyloid fractions produced by both viruses had more than 40% of the enriched proteins that were shared, while the amyloid fractions produced by HSV-1 had 37%, and SARS-CoV-2 had 23% unique proteins.
We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Endogenous exosomes act as decoys for SARS-CoV-2Endogenous exosomes act as decoys for SARS-CoV-2 Exosomes SARSCoV2 Coronavirus Disease COVID Tolllikereceptors Autophagic Interferons PLOSBiology UZH_ch UZH_Virology
Source: NewsMedical - 🏆 19. / 71 Read more »
New mechanistic insights on the origin of SARS-CoV-2-induced neurological disordersNew mechanistic insights on the origin of SARS-CoV-2-induced neurological disorders biorxivpreprint umontpellier IRIM_life unistra SARSCoV2 COVID19 coronavirus neurological disease disorder
Source: NewsMedical - 🏆 19. / 71 Read more »
The potential of nanobody engineering in the development of SARS-CoV-2 antivirals and diagnostic toolsThe potential of nanobody engineering in the development of SARS-CoV-2 antivirals and diagnostic tools biorxivpreprint helsinkiuni UZH_en LivUni nanobody SARSCoV2 antiviral covid coronavirus covid diagnosis
Source: NewsMedical - 🏆 19. / 71 Read more »
What is the SARS-CoV-2 transmissibility among United States residents?In a new study, researchers estimated region-specific basic reproduction number (R0) values for metropolitan statistical areas in the US, based on compartmental modeling with reproduced SARS-CoV-2 surveillance data.
Source: NewsMedical - 🏆 19. / 71 Read more »
Is there any impact of COVID-19 vaccines on the fertility of men and women of reproductive age?Is there any impact of COVID-19 vaccines on the fertility of men and women of reproductive age? Unicatt COVID19 coronavirus covid ferility SARSCoV2 reproductivehealth
Source: NewsMedical - 🏆 19. / 71 Read more »
A critical overview of current progress for COVID-19: development of vaccines, antiviral drugs, and therapeutic antibodies - Journal of Biomedical ScienceThe novel coronavirus disease (COVID-19) pandemic remains a global public health crisis, presenting a broad range of challenges. To help address some of the main problems, the scientific community has designed vaccines, diagnostic tools and therapeutics for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. The rapid pace of technology development, especially with regard to vaccines, represents a stunning and historic scientific achievement. Nevertheless, many challenges remain to be overcome, such as improving vaccine and drug treatment efficacies for emergent mutant strains of SARS-CoV-2. Outbreaks of more infectious variants continue to diminish the utility of available vaccines and drugs. Thus, the effectiveness of vaccines and drugs against the most current variants is a primary consideration in the continual analyses of clinical data that supports updated regulatory decisions. The first two vaccines granted Emergency Use Authorizations (EUAs), BNT162b2 and mRNA-1273, still show more than 60% protection efficacy against the most widespread current SARS-CoV-2 variant, Omicron. This variant carries more than 30 mutations in the spike protein, which has largely abrogated the neutralizing effects of therapeutic antibodies. Fortunately, some neutralizing antibodies and antiviral COVID-19 drugs treatments have shown continued clinical benefits. In this review, we provide a framework for understanding the ongoing development efforts for different types of vaccines and therapeutics, including small molecule and antibody drugs. The ripple effects of newly emergent variants, including updates to vaccines and drug repurposing efforts, are summarized. In addition, we summarize the clinical trials supporting the development and distribution of vaccines, small molecule drugs, and therapeutic antibodies with broad-spectrum activity against SARS-CoV-2 strains.
Source: BioMedCentral - 🏆 22. / 71 Read more »